Abstract：
UNASSIGNED: Genetic polymorphisms play a crucial role in predicting treatment efficacy in patients with hepatocellular carcinoma (HCC). This study aims to evaluate the response to Transarterial Chemoembolization (TACE) in relation to the genetic polymorphisms of interleukin 28B (IL28B) and angiopoietin-2 (ANGPT2) in HCC patients.
UNASSIGNED: Prospective cohort study conducted on 104 eligible HCC Egyptian patients who underwent TACE using doxorubicin and lipiodol. Genotyping of the IL28B and ANGPT2 genes was performed with laboratory data analysis.
UNASSIGNED: At baseline IL28B rs12979860 genotypes C/T, C/C and T/T appeared in 43.9%, 34.6% and 21.5% while ANGPT2 rs55633437 genotypes C/C, C/A and A/A found in 71.03%, 28.04% and 0.93% of patients respectively. After one month of therapy, 51.4% of patients achieved a complete response. There was a significant difference in relation to IL28B rs12979860 genotypes (p = 0.017) whereas ANGPT2 rs55633437 genotypes (p = 0.432) showed no significant difference in patient response after one month of TACE.
UNASSIGNED: This study demonstrates the effectiveness of TACE in Egyptian HCC patients, as evidenced by low recurrence rates. Furthermore, the IL28B rs12979860 (C/T) gene may be associated with the efficacy and prognosis of TACE treatment in HCC Egyptian patients.
UNASSIGNED: The trial is registered at ClinicalTrials.gov (CT.gov identifier: NCT05291338).
UNASSIGNED: Prospective cohort study conducted on 104 eligible HCC Egyptian patients who underwent TACE using doxorubicin and lipiodol. Genotyping of the IL28B and ANGPT2 genes was performed with laboratory data analysis.
UNASSIGNED: At baseline IL28B rs12979860 genotypes C/T, C/C and T/T appeared in 43.9%, 34.6% and 21.5% while ANGPT2 rs55633437 genotypes C/C, C/A and A/A found in 71.03%, 28.04% and 0.93% of patients respectively. After one month of therapy, 51.4% of patients achieved a complete response. There was a significant difference in relation to IL28B rs12979860 genotypes (p = 0.017) whereas ANGPT2 rs55633437 genotypes (p = 0.432) showed no significant difference in patient response after one month of TACE.
UNASSIGNED: This study demonstrates the effectiveness of TACE in Egyptian HCC patients, as evidenced by low recurrence rates. Furthermore, the IL28B rs12979860 (C/T) gene may be associated with the efficacy and prognosis of TACE treatment in HCC Egyptian patients.
UNASSIGNED: The trial is registered at ClinicalTrials.gov (CT.gov identifier: NCT05291338).
摘要：
■遗传多态性在预测肝细胞癌（HCC）患者的治疗效果中起着至关重要的作用。本研究旨在评估HCC患者对经动脉化疗栓塞（TACE）的反应与白细胞介素28B（IL28B）和血管生成素2（ANGPT2）的遗传多态性有关。
■对104例接受TACE治疗的埃及肝癌患者进行前瞻性队列研究。用实验室数据分析进行IL28B和ANGPT2基因的基因分型。
■在基线IL28Brs12979860基因型C/T，C/C和T/T出现在43.9%，34.6%和21.5%，而ANGPT2rs55633437基因型为C/C，C/A和A/A发现71.03%，分别为28.04%和0.93%。经过一个月的治疗，51.4%的患者达到完全缓解。与IL28Brs12979860基因型之间存在显着差异（p=0.017），而ANGPT2rs55633437基因型（p=0.432）在TACE一个月后的患者反应中没有显着差异。结论：本研究证明了TACE在埃及HCC患者中的有效性，低复发率证明了这一点。此外，IL28Brs12979860(C/T)基因可能与埃及HCC患者TACE治疗的疗效和预后相关.
■该试验已在ClinicalTrials.gov注册（CT.gov标识符：NCT05291338）。
■对104例接受TACE治疗的埃及肝癌患者进行前瞻性队列研究。用实验室数据分析进行IL28B和ANGPT2基因的基因分型。
■在基线IL28Brs12979860基因型C/T，C/C和T/T出现在43.9%，34.6%和21.5%，而ANGPT2rs55633437基因型为C/C，C/A和A/A发现71.03%，分别为28.04%和0.93%。经过一个月的治疗，51.4%的患者达到完全缓解。与IL28Brs12979860基因型之间存在显着差异（p=0.017），而ANGPT2rs55633437基因型（p=0.432）在TACE一个月后的患者反应中没有显着差异。结论：本研究证明了TACE在埃及HCC患者中的有效性，低复发率证明了这一点。此外，IL28Brs12979860(C/T)基因可能与埃及HCC患者TACE治疗的疗效和预后相关.
■该试验已在ClinicalTrials.gov注册（CT.gov标识符：NCT05291338）。
